Strategies to Provide Individualized Treatment in Moderate-to-Severe Atopic Dermatitis
Release Date: December 7, 2018
Expiration Date: December 7, 2019
Estimated Time to Completion: 0.75 hour(s)
Faculty
Amy S. Paller, MS, MD
Chair, Department of Dermatology
Director, Northwestern University Skin Disease Research Center
Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
Jonathan M. Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Endowed Chair of Pediatrics
Director, Center for Pediatric Eosinophilic Disease
Director, FARE Center of Excellence
The Children's Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Target Audience
This educational initiative has been designed for dermatologists, allergists, primary care physicians, nurse practitioners, and physician assistants involved in the management of atopic dermatitis (AD).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
Utilize updated criteria and guidelines to accurately diagnose AD and assess severity
Describe the limitations of currently available therapies in addressing underlying AD pathophysiology
Evaluate recent clinical evidence on the utility of approved and emerging biologic agents to address the underlying pathophysiology of AD
Discuss strategies that will improve patient satisfaction with treatment and reduce the burden of comorbidities
Directions to the Learner
There are no fees for participating and receiving CME credit for this activity. During the period of December 7, 2018 through December 7, 2019 participants must:
Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Accreditation
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Provided by Integrity Continuing Education, Inc. Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Director, Northwestern University Skin Disease Research Center
Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
Amy S. Paller, MS, MD, is the Chair and Walter J. Hamlin Professor in the Department of Dermatology in the Feinberg School of Medicine at Northwestern University. She is also the Director of the Northwestern University Skin Disease Research Center and a Professor of Pediatrics.
Dr. Paller is board certified in pediatrics, dermatology, and pediatric dermatology. She holds a medical degree from Stanford University School of Medicine, and a master of science degree in genetics from Brown University. Dr. Paller completed her internship and residencies in pediatrics and dermatology at Northwestern University, and her fellowship in dermatology at the University of North Carolina School of Medicine.
Dr. Paller has been a leader of several international, national, and local societies, among them as President of the Society for Investigative Dermatology (SID), the Society for Pediatric Dermatology, the International Eczema Council, and currently the International Society for Pediatric Dermatology. She has been the recipient of numerous honors, among them the Stephen Rothman Award of the SID, the Clarence Livingood Award of the American Academy of Dermatology, and the Wilma Bergfeld, MD Visioning and Leadership Award from the Women's Dermatological Society. A National Institutes of Health-funded investigator, she currently serves on the Council for the National Institute for Arthritis, Musculoskeletal and Skin Diseases. Dr. Paller serves on multiple editorial and advisory boards, and is both an editorial and grant reviewer. Dr. Paller has published almost 600 research articles, book chapters, and other contributions to the scientific literature. Her clinical and research interests include atopic dermatitis, psoriasis,
genetic skin problems, diabetic ulcers, and nanotechnology approaches for topically-delivered gene therapy.
Jonathan M. Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Endowed Chair of Pediatrics
Director, Center for Pediatric Eosinophilic Disease
Director, FARE Center of Excellence
The Children's Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Jonathan M. Spergel, MD, PhD, is a Professor of Pediatrics, Chief of the Allergy Section, and Stuart E. Starr Endowed Chair of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania. He is also the Director of the Center for Pediatric Eosinophilic Disease and the Director of the Food Allergy Research Education Center of Excellence at The Children's Hospital of Philadelphia.
Dr. Spergel is board certified in pediatrics, allergy, and immunology. He holds a medical degree and doctor of philosophy degree in biomedical sciences from Mount Sinai School of Medicine. Dr. Spergel completed his internship and residency in pediatrics at Yale-New Haven Hospital, and his fellowship in allergy and immunology at Children's Hospital in Boston.
Dr. Spergel has been named a Top Doctor by Castle Connolly and a Top Doc with National Distinction by US News and World Report for several years. He is a fellow of the American College of Allergy, Asthma, and Immunology and the American Academy of Allergy, Asthma, and Immunology, and has held multiple leadership positions with both groups. Dr. Spergel is also a fellow of the American Academy of Pediatrics and belongs to several other national and local societies. He serves on the editorial boards of multiple scientific journals, and has published over 100 peer-reviewed research publications. His clinical and research interests include asthma, atopic dermatitis, allergic rhinitis, and food allergy.
Learning Objectives
Utilize updated criteria and guidelines to accurately diagnose atopic dermatitis (AD) and assess severity
Describe the limitations of currently available therapies in addressing underlying AD pathophysiology
Evaluate recent clinical evidence on the utility of approved and emerging biologic agents to address the underlying pathophysiology of AD
Discuss strategies that will improve patient satisfaction with treatment and reduce the burden of comorbidities
Disease Overview
Cycle of itching and scratching
Cellular damage and secondary infections
Eczematous lesions associated with Th2 and Th22 inflammation
Utilize updated criteria and guidelines to accurately diagnose atopic dermatitis (AD) and assess severity
Describe the limitations of currently available therapies in addressing underlying AD pathophysiology
Evaluate recent clinical evidence on the utility of approved and emerging biologic agents to address the underlying pathophysiology of AD
Discuss strategies that will improve patient satisfaction with treatment and reduce the burden of comorbidities
